Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1297

1.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
[PubMed - indexed for MEDLINE]
2.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
[PubMed - indexed for MEDLINE]
3.

Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.

Antivir Ther. 2004 Oct;9(5):713-9.

PMID:
15535408
[PubMed - indexed for MEDLINE]
4.

Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.

Moore DM, Hogg RS, Yip B, Wood E, Tyndall M, Braitstein P, Montaner JS.

J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):288-93.

PMID:
16249702
[PubMed - indexed for MEDLINE]
5.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
[PubMed - indexed for MEDLINE]
6.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
[PubMed - indexed for MEDLINE]
7.

"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.

Wood E, Hogg RS, Yip B, Tyndall MW, Sherlock CH, Harrigan RP, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):159-66.

PMID:
12045678
[PubMed - indexed for MEDLINE]
8.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
[PubMed - indexed for MEDLINE]
9.

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy.

Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L.

Ann Intern Med. 2000 Sep 19;133(6):401-10.

PMID:
10975957
[PubMed - indexed for MEDLINE]
10.

Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?

Mocroft A, Gill MJ, Davidson W, Phillips AN.

J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):475-82.

PMID:
11035619
[PubMed - indexed for MEDLINE]
11.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.

Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, Tyrer M, Loveday C, Phillips AN, Johnson MA.

AIDS. 2000 Jul 28;14(11):1545-52.

PMID:
10983641
[PubMed - indexed for MEDLINE]
12.

Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.

Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S; CoRIS-MD.

PLoS One. 2006 Dec 20;1:e89.

PMID:
17183720
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.

Mocroft, Horban, Clumeck, Stellbrink, Monforte dA, Zilmer, Kirk, Gatell, Phillips, Lundgren; EuroSIDA Study Group.

HIV Clin Trials. 2006 Nov-Dec;7(6):271-84.

PMID:
17208897
[PubMed - indexed for MEDLINE]
Free Article
14.

Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.

Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C.

AIDS Patient Care STDS. 2008 Apr;22(4):301-12. doi: 10.1089/apc.2007.0101.

PMID:
18338961
[PubMed - indexed for MEDLINE]
15.

Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.

Servais J, Schmit JC, Arendt V, Lambert C, Staub T, Robert I, Fontaine E, Plesséria JM, Burgy C, Kirpach P, Schneider F, Hemmer R.

HIV Clin Trials. 2000 Sep-Oct;1(2):17-24.

PMID:
11590494
[PubMed - indexed for MEDLINE]
16.

Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors.

Knobel H, Guelar A, Carmona A, Espona M, González A, López-Colomés JL, Saballs P, Gimeno JL, Díez A.

AIDS Patient Care STDS. 2001 Apr;15(4):193-9.

PMID:
11359661
[PubMed - indexed for MEDLINE]
17.

Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.

Deeks SG, Barbour JD, Grant RM, Martin JN.

AIDS. 2002 Jan 25;16(2):201-7.

PMID:
11807304
[PubMed - indexed for MEDLINE]
18.

Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

HIV Med. 2007 Mar;8(2):80-5.

PMID:
17352763
[PubMed - indexed for MEDLINE]
19.

Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.

Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS.

AIDS. 2006 May 12;20(8):1117-23.

PMID:
16691062
[PubMed - indexed for MEDLINE]
20.

Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.

Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.

Antivir Ther. 2005;10(7):849-53.

PMID:
16312181
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk